Logo

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

Share this

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

Shots:

  • The REALITI-A study involves assessing of Nucala (100mg- SC) in 368 patients with severe eosinophilic asthma- being conducted in a routine care setting- compared to the prior 12mos.
  • The REALITI-A study results: annual reduction rate in exacerbations (69%); reduction in exacerbations requiring hospitalization/emergency room visits (77%); reduction in m-oral corticosteroid (OCS) dose 10 mg/day to 5mg/day with 34% of patients able to stop OCS completely- study is expected to be completed in 2021
  • Nucala is mAb targeting IL-5- prevent its binding to its receptor on the surface of eosinophils- reducing blood eosinophils without completely depleting them and is an approved therapy in the US- EU & 20+ countries as an add-on maintenance treatment for patients with SEA

Click here to­ read full press release/ article 

Ref: GSK | Image: GSK


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions